Specifically Regulating Tumor Microenvironment by a Gemcitabine@Nanogel System via in vitro 3D Model for Synergistic Pancreatic Cancer Therapy

2019 ◽  
Author(s):  
Di Chen ◽  
Xiaofei Zhu ◽  
Ri Liu ◽  
Yajun Zhang ◽  
Wanru Tao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
3D Model ◽  
Pancreatic Cancer Therapy

scholarly journals siRNA-Loaded Hydroxyapatite Nanoparticles for KRAS Gene Silencing in Anti-Pancreatic Cancer Therapy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1428
Author(s):  
Dandan Luo ◽  
Xiaochun Xu ◽  
M. Zubair Iqbal ◽  
Qingwei Zhao ◽  
Ruibo Zhao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Gene Silencing ◽  
Targeted Delivery ◽  
High Efficiency ◽  
Great Promise ◽  
Kras Gene ◽  
Promising Alternative ◽  
Pancreatic Cancer Therapy

Pancreatic carcinoma (PC) is greatly induced by the KRAS gene mutation, but effective targeted delivery for gene therapy has not existed. Small interfering ribonucleic acid (siRNA) serves as an advanced therapeutic modality and holds great promise for cancer treatment. However, the development of a non-toxic and high-efficiency carrier system to accurately deliver siRNA into cells for siRNA-targeted gene silencing is still a prodigious challenge. Herein, polyethylenimine (PEI)-modified hydroxyapatite (HAp) nanoparticles (HAp-PEI) were fabricated. The siRNA of the KRAS gene (siKras) was loaded onto the surface of HAp-PEI via electrostatic interaction between siRNA and PEI to design the functionalized HAp-PEI nanoparticle (HAp-PEI/siKras). The HAp-PEI/siKras was internalized into the human PC cells PANC-1 to achieve the maximum transfection efficiency for active tumor targeting. HAp-PEI/siKras effectively knocked down the expression of the KRAS gene and downregulated the expression of the Kras protein in vitro. Furthermore, the treatment with HAp-PEI/siKras resulted in greater anti-PC cells’ (PANC-1, BXPC-3, and CFPAC-1) efficacy in vitro. Additionally, the HAp-PEI exhibited no obvious in vitro cytotoxicity in normal pancreatic HPDE6-C7 cells. These findings provided a promising alternative for the therapeutic route of siRNA-targeted gene engineering for anti-pancreatic cancer therapy.

scholarly journals Impacting Pancreatic Cancer Therapy in Heterotypic in Vitro Organoids and in Vivo Tumors with Specificity-Tuned, NIR-Activable Photoimmunonanoconjugates: Towards Conquering Desmoplasia?

Nano Letters ◽  
2019 ◽  
Vol 19 (11) ◽  
pp. 7573-7587 ◽  
Author(s):  
Girgis Obaid ◽  
Shazia Bano ◽  
Srivalleesha Mallidi ◽  
Mans Broekgaarden ◽  
Jerrin Kuriakose ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Pancreatic Cancer Therapy

Regulation of tumor microenvironment for pancreatic cancer therapy

Biomaterials ◽  
2021 ◽  
Vol 270 ◽  
pp. 120680
Author(s):  
Xu Huang ◽  
Lei Ding ◽  
Xingkai Liu ◽  
Rongsheng Tong ◽  
Jianxun Ding ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Tumor Microenvironment ◽  
Cancer Therapy ◽  
Pancreatic Cancer Therapy

Sa1445 A Novel Use of a Second Generation Photosensitizer Agent Combined With Gemcitabine for Pancreatic Cancer Therapy: In Vitro and In Vivo Results

2013 ◽  
Vol 77 (5) ◽  
pp. AB208-AB209
Author(s):  
Gang Sun ◽  
Marlys Anderson ◽  
Emmanuel C. Gorospe ◽  
Margriet R. Timmer ◽  
Cadman L. Leggett ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Second Generation ◽  
Pancreatic Cancer Therapy

Preparation, characterization and in vitro evaluation of ε-polylysine-loaded polymer blend microparticles for potential pancreatic cancer therapy

2017 ◽  
Vol 34 (6) ◽  
pp. 582-591 ◽  
Author(s):  
Merari T. Chevalier ◽  
Mónica C. García ◽  
Daniela Gonzalez ◽  
Sandro M. Gomes-Filho ◽  
Daniela S. Bassères ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Therapy ◽  
Polymer Blend ◽  
In Vitro Evaluation ◽  
Pancreatic Cancer Therapy
Sign in / Sign up

Export Citation Format

Share Document